NMRD NEMAURA MEDICAL

Nemaura Medical to Ring the Nasdaq Closing Bell

LOUGHBOROUGH, England--(BUSINESS WIRE)--

Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that Bashir Timol, Director of Strategy and Corporate Development, will ring the closing bell of the Nasdaq Stock Market on Tuesday, March 6, 2018 at 4:00 pm ET.

Mr. Timol will be ringing the bell in honor of the Company’s recent uplisting to the Nasdaq Capital Market.

A live stream of the Nasdaq Closing Bell will be available at:

https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

About Nemaura Medical, Inc.

Nemaura Medical Inc. (NASDAQ: NMRD), is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by persons with diabetes. SugarBEAT® consists of a disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings. For more information, please visit www.NemauraMedical.com and www.SugarBEAT.com.

EN
06/03/2018

Underlying

NMRDNEMAURA MEDICAL

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEMAURA MEDICAL

 PRESS RELEASE
Free
NMRD NEMAURA MEDICAL

Nemaura Medical Reports Results and Provides Business Update for the T...

Nemaura Medical Reports Results and Provides Business Update for the Third Quarter Ended December 31, 2019 Loughborough, England, Feb. 11, 2020 (GLOBE NEWSWIRE) --   (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a business update and financial results for the third quarter ended December 31,...

February 11, 2020 1 EN
 PRESS RELEASE
Free
NMRD NEMAURA MEDICAL

Nemaura Provides 2019 Year-End Corporate Update

Nemaura Provides 2019 Year-End Corporate Update Loughborough, England, Dec. 20, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a 2019 year-end corporate update. Dr. Faz Chowdhury, CEO of Nemaura, stated, “2019 was a transformative year for our Company as w...

December 20, 2019 1 EN
 PRESS RELEASE
Free
NMRD NEMAURA MEDICAL

Nemaura Medical and Changing Health announce Partnership to provide aw...

Nemaura Medical and Changing Health announce Partnership to provide award-winning Diabetes Behavioral Change services Nemaura and Changing Health to provide innovative digital education and personalized coaching to enhance outcomes for people with diabetes and prediabetes Loughborough, England, Dec. 17, 2019 (GLOBE NEWSWIRE) --    () (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes through per...

December 17, 2019 1 EN
 PRESS RELEASE
Free
NMRD NEMAURA MEDICAL

Nemaura Medical announces expansion of SugarBEAT® offering  with BEA...

Nemaura Medical announces expansion of SugarBEAT® offering  with BEAT® Diabetes digital subscription services  BEAT® Diabetes utilizes SugarBEAT® CGM data to provide holistic coaching services via user-friendly app to enhance outcomes for diabetic and pre-diabetic patients Loughborough, England, Dec. 05, 2019 (GLOBE NEWSWIRE) --   () (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for diabetics and pre-diabetics, announced that it has expanded its SugarBEAT® CGM capabilit...

December 5, 2019 1 EN
 PRESS RELEASE
Free
NMRD NEMAURA MEDICAL

Nemaura Medical Announces 1 for 10 Reverse Split Intended to Attract ...

Nemaura Medical Announces 1 for 10 Reverse Split Intended to Attract a Wider Universe of Institutional Investors Loughborough, England, Dec. 04, 2019 (GLOBE NEWSWIRE) --   (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced plans to conduct reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share on a one 1 for 10 basis.  The reverse split is expected to take effe...

December 4, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch